News

The FBP vaccine is a composition of E39 peptide combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). RXi Pharma president and CEO Mark Ahn said

The results from two previous Phase I trial demonstrated that the drug was safe and well tolerated when administered in healthy volunteers. NI-0801 is a fully human monoclonal

CF-301, produced by fermentation at concentrations exceeding 5g/l, is soluble, stable and potent. The Lysins possess a therapeutic window that occurs virtually instantly while the Monoclonal Antibodies remain

As per the previous agreement, both the firms collaborated for the commercialization of Sinclair’s dermatology brands in eleven Asia Pacific countries. Under an agreement, the companies have launched

The US patent no. 8,022,279 includes the key composition features of CPX-351, a liposome formulation that co-encapsulates cytarabine and daunorubicin at a synergistic 5:1 molar ratio. Additionally, the

Under the deal, both the firms have agreed to collaborate on the development of bacteriophage (or phage) based technology for a range of applications. Intralytix CEO John Woloszyn

Xeloda Tablets, 150mg and 500mg, USP are indicated as a treatment of metastatic breast and colorectal cancers. Pursuant to the agreement, the litigation was dismissed on 21 September

The agreement allows FKD to develop and commercialise Merck’s recombinant adenoviral interferon alfa 2b (rAd-IFN) to treat superficial bladder cancer. The agreement also includes an option to develop

Under the contract, the companies will use Vernalis’ fragment and structure-based drug discovery platform against LRRK2. As per the terms of the deal, Vernalis is entitled to receive